摘要
目的探讨维奈克拉联合胞嘧啶核苷类药物对急性髓系白血病患者巨噬细胞炎症蛋白-1α(MIP-1α)、肿瘤相关巨噬细胞(TAM,CD206^(+))、免疫调节指标(CD4^(+)/CD8^(+))及不良反应发生率的影响。方法选取我院2019年5月至2021年3月收拾的86例急性髓系白血病患者作为研究对象。按照随机数字表法分为观察组(n=43例)和对照组(n=43例)。对照组患者给予阿扎胞苷治疗,观察组在对照组的基础上增加维奈克拉治疗。比较两组患者治疗前后MIP-1α、CD206^(+)、CD4^(+)/CD8^(+)指标水平的变化、缓解情况、不良反应发生情况。结果观察组治疗后MIP-1α、CD206^(+)、CD4^(+)/CD8^(+)表达水平分别为(161.62±40.43)pg/ml、(2.35±0.98)%、(1.21±0.15)%,对照组治疗后MIP-1α、CD206^(+)、CD4^(+)/CD8^(+)表达水平分别为(180.15±45.53)pg/ml、(3.57±1.21)%、(1.32±0.18)%,两组患者上述指标水平同治疗前比较表达水平均有所改善,且观察组改善更加明显(P<0.05);观察组患者治疗后完全缓解18例、部分缓解16例、未缓解9例,临床总有效率为79.05%,对照组患者治疗后完全缓解8例、部分缓解13例、未缓解22例,临床总缓解率为48.84%,观察组患者临床总缓解率高于对照组(P<0.05);观察组患者治疗后肝功能异常2例、肺部感染2例、恶心与呕吐3例,不良反应总发生率为16.28%,对照组患者治疗后肝功能异常3例、肺部感染2例、恶心与呕吐4例,不良反应总发生率为20.93%,两组患者临床不良反应发生率比较(P>0.05)。结论奈克拉联合阿扎胞苷治疗急性髓系白血病能有效改善MIP-1α、CD206^(+)、CD4^(+)/CD8^(+)指标水平的变化,改善免疫功能、具有较好的临床疗效和安全性。
Objective To investigate the effects of Venetoclax combined with Azacitidine on macrophage inflammatory protein-lα(MIP-lα),tumor-associated macrophages(TAM,CD206^(+)),immunoregulatory parameters(CD4^(+)/CD8^(+))and the incidence of adverse reactions in patients with acute myeloid leukemia.MethodssEighty-six patients with acute myeloid leukemia who were admitted to our hospital from May 2019 to March 2021 were selected and divided into an observation group(n=43)and a control group(n=43)according to random number table.The patients in the control group were treated with azacitidine,and the patients in the observation group were treated with Venetoclax on the basis of the control group.The changes of MIP-1α,CD206^(+),and CD4^(+)/CD8^(+)levels,remission,and occurrence of adverse reactions before and after treatment were compared between the two groups.ResultssAfter treatment,the expression levels of MIP-1α,CD206^(+)and CD4^(+)/CD8^(+)in the observation group were(161.62±40.43)pg/ml,(2.35±0.98)%and(1.21±0.15)%,respectively.After treatment,the expression levels of MIP-1α,CD206^(+)and CD4^(+)/CD8^(+)in the control group were(180.15±45.53)pg/ml,(3.57±1.21)%and(1.32±0.18)%,respectively.The expression levels of the above indicators in the two groups were improved compared with those before treatment,and the improvement was more significant in the observation group(P<0.05).After treatment,18 patients in the observation group had complete remission,16 patients had partial remission and 9 patients had no remission,with an overall clinical response rate of 79.05%.After treatment,8 patients in the control group had complete remission,13 patients had partial remission and 22 patients had no remission,with an overall clinical remission rate of 48.84%.The overall clinical remission rate in the observation group was higher than that in the control group(P<0.05).There were 2 cases of abnormal liver function,2 cases of pulmonary infection,3 cases of nausea and vomiting after treatment in the observation group,with the tota
作者
钟林达
Zhong Linda(The First Affiliated Hospital of Henan University of Science and Technology,Luoyang,Henan 471000)
出处
《辽宁医学杂志》
2023年第3期21-24,共4页
Medical Journal of Liaoning
